SRR614155
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.419
- KRAS_SIGNALING_DN+0.339
- COAGULATION+0.193
- BILE_ACID_METABOLISM+0.186
- APICAL_JUNCTION+0.167
- ESTROGEN_RESPONSE_LATE+0.158
- ESTROGEN_RESPONSE_EARLY+0.153
- APICAL_SURFACE+0.152
- KRAS_SIGNALING_UP+0.143
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.134
Top 10 suppressed
- MYC_TARGETS_V1-0.533
- MYC_TARGETS_V2-0.529
- MTORC1_SIGNALING-0.466
- E2F_TARGETS-0.460
- DNA_REPAIR-0.438
- G2M_CHECKPOINT-0.427
- UNFOLDED_PROTEIN_RESPONSE-0.425
- PROTEIN_SECRETION-0.417
- CHOLESTEROL_HOMEOSTASIS-0.399
- TNFA_SIGNALING_VIA_NFKB-0.372
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR612899 | GTEX | — | 0.945 |
| 2 | SRR1339530 | GTEX | — | 0.936 |
| 3 | SRR665298 | GTEX | — | 0.925 |
| 4 | SRR1476279 | GTEX | — | 0.914 |
| 5 | SRR602540 | GTEX | — | 0.910 |
| 6 | SRR598276 | GTEX | — | 0.908 |
| 7 | SRR1406976 | GTEX | — | 0.906 |
| 8 | SRR1472079 | GTEX | — | 0.905 |
| 9 | SRR614814 | GTEX | — | 0.903 |
| 10 | SRR1334741 | GTEX | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.419 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.339 | Remibrutinib | — uncovered |
| COAGULATION | 0.193 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.186 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.167 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.158 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.153 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.152 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.143 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.134 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.119 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.106 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.105 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.094 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.084 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.081 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.052 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.021 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.007 | Remibrutinib | — uncovered |